Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2
Active, not recruiting · Not applicable · NCT02777593
Conditions: Aortic Aneurysm, Thoracic, Aorta, Lesion
At a glance
- Research payments reported, 2025
- $49,366
- U.S. investigators named
- 14
- Sites paid
- 20
- Planned or actual enrollment
- 250
About the trial
- Sponsor
- W.L.Gore & Associates
- Tested
- GORE® TAG® Thoracic Branch Endoprosthesis (device)
- Dates
- Started 2016-09-06; completion 2027-12
- Results posted
- Yes
The objective of this study is to determine whether the GORE® TAG® Thoracic Branch Endoprosthesis is safe and effective in treating lesions of the aortic arch and descending thoracic aorta, requiring Zone 2 proximal implantation of the device.
From ClinicalTrials.gov, last updated 2026-09-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
W. L. Gore & Associates, Inc. reported $49,366 in research payments for this study in 2025 (30 payments).
Products named: Product in Development, Gore Tag Thoracic Branch Endoprosthesis
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Murray L. Shames, MD Vascular Surgery · Tampa, FL
- Bradley G. Leshnower, MD Cardiothoracic Surgery · Atlanta, GA
- Sina L. Moainie, MD Cardiothoracic Surgery · Carmel, IN
- Stanley J. Chetcuti, MD Cardiology · Ann Arbor, MI
- Randall R. Demartino, M.D. Vascular Surgery · Rochester, MN
- Andrew W. Hoel, M.D. Vascular Surgery · Rochester, MN
- Frank R. Arko III, MD Vascular Surgery · Charlotte, NC
- George C. Hughes IV, M.D. Cardiothoracic Surgery · Lumberton, NC
- Bjoern D. Suckow, M.D. Vascular Surgery · Lebanon, NH
- Matthew J. Eagleton, MD Vascular Surgery · Cleveland, OH
- Nimesh D. Desai, MD Cardiothoracic Surgery · Philadelphia, PA
- William Brinkman, MD Cardiothoracic Surgery · Plano, TX
- David J. Dexter II, MD Vascular Surgery · Norfolk, VA
- Matthew P. Sweet, M.D. Vascular Surgery · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Massachusetts General Hospital, MA $8,900
- Emory University Hospital, GA $8,138
- Pennsylvania Hospital, PA $4,616
- Harborview Medical Center, WA $4,540
- Baylor Research Institute $4,097
- University of Maryland Medical Center, MD $3,096
- Duke University Hospital, NC $2,556
- Cedars-Sinai Medical Center, CA $1,875
- Ascension Medical Group Saint Vincent Indianapolis Cardiology $1,750
- Mary Hitchcock Memorial Hospital, NH $1,736
- Northwestern University $1,565
- University of Wi Hospitals & Clinics Authority, WI $1,556
- Keck Hospital of Usc, CA $1,500
- Sentara Medical Group $1,150
- University of Michigan Health System, MI $1,043
- Hartford Hospital, CT $650
- Mayo Clinic $226
- Ohsu Hospital and Clinics, OR $160
- Carolinas Health Care System $114
- Usf Health $98
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.